GTG tightens patent grip
18 November, 2003 by Graeme O'NeillMelbourne company Genetic Technologies Ltd (ASX: GTG) has settled two of three lawsuits brought against US biotechnology companies for alleged infringements of its non-coding DNA gene-testing patents.
GM surgery to detoxify feed crop
17 November, 2003 by Graeme O'NeillMolecular geneticists at Melbourne University's Institute of Land and Food Resources plan to use RNA interference gene silencing to remove a potent neurotoxin from the manure and feed crop, vetch (Vicia sativa).
CEO change off the agenda at Ventracor AGM
14 November, 2003 by Andrew BirminghamShareholders at Ventracor's annual general meeting in Brisbane yesterday raised not a jot of concern about the board's surprise decision this week to replace CEO Michael Spooner with former Sirtex chief Colin Sutton.
Ex-Novartis CEO joins Pharmaxis
14 November, 2003 by Melissa TrudingerNewly-listed company Pharmaxis (ASX:PXS) has appointed ex-Novartis Australia CEO Gary Phillips as commercial director to look after sales and marketing efforts as the company prepares to complete clinical trials and roll out its first product.
AustCancer in gene test partnership
14 November, 2003 by Melissa TrudingerAustralian Cancer Technology (ASX:ACU) has partnered with Prof Ursula Kees at the Telethon Institute for Child Health Research to develop a diagnostic test able to rapidly screen tumour samples for deleted tumour suppressor genes.
Local researchers abuzz for bee genome publication
13 November, 2003 by Melissa TrudingerWith the honeybee genome about to be completed, work is ramping up in Assoc Prof Ben Oldroyd's laboratory at the University of Sydney to take advantage of the information it offers.
Bayer off the hook in NSW canola trial
12 November, 2003 by Graeme O'NeillNSW Agriculture Minister Ian MacDonald has advised Bayer CropScience that it will not have to destroy a trial crop of genetically modified herbicide-tolerant canola near Wagga, despite the discovery of a small number of canola plants in the surrounding buffer zone.
Premier in hunt for commercial partner
12 November, 2003 by Melissa TrudingerPremier Bionics (ASX:PBI) is ramping up its efforts to find a commercial partner for its Airway Clear sleep apnoea monitoring device.
Epitan: FDA intrigued by tanning drug
12 November, 2003 by Melissa TrudingerEpitan (ASX:EPT) has returned from its pre-IND meeting with the US Food and Drug Administration with a clear idea of what will be required to get approval for US clinical trials, according to CEO Wayne Millen.
Biotech veteran calls for tax breaks
12 November, 2003 by Melissa TrudingerLong time biotechnology investor Leon Serry has called on the federal government to implement a 100 per cent tax deduction as an incentive for significant institutional investment into Australian companies running Phase III clinical trials.
Analysts surprised by Pharmaxis' early drop
11 November, 2003 by Melissa TrudingerSydney-based pharmaceutical company Pharmaxis (ASX:PXS) listed on the ASX on Monday after successfully raising AUD$25 million in its IPO last month.
Arthron arthritis candidate a stayer
11 November, 2003 by Graeme O'NeillMelbourne biotechnology company Prima Biomed (ASX:PRR) is chuffed with an intriguing result reported by its subsidiary Arthron from trials of its experimental rheumatoid arthritis drugs in mice.
Spooner replaced as Ventracor CEO
11 November, 2003 by Melissa TrudingerFormer Sirtex Medical CEO Dr Colin Sutton has today taken over as chief of artificial heart company Ventracor (ASX:VCR), replacing Michael Spooner.
Alchemia launches $21m IPO
10 November, 2003 by Melissa TrudingerBrisbane-based carbohydrates company Alchemia is the latest company to seek listing on the ASX, announcing a AUD$21 million IPO to take place before Christmas.
Vision Bio takes aim at US market
07 November, 2003 by Melissa TrudingerMelbourne-based research instrument developer Vision BioSystems is gearing up to launch its Bond-X immunohistochemistry system in the US before the end of the year.
